MARKET WIREYahoo Finance UK • 18h ago
Quanterix Corporation (QTRX) Seasonal returns chartYahoo Finance UK report covering Quanterix Corporation (QTRX) market action, institutional positioning, and fundamental catalysts.
Why QTRX Stock dropped -7.63% Today — RQD Quant Desk Flash
$2.91 -7.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.86
Quanterix Corporation (QTRX) carries a Roarable Rating of E (Strong Sell) with 22/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $137.4M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on QTRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is QTRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Quanterix Corporation (NASDAQ: QTRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $2.91 (-7.63% 1D, market cap $137.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, QTRX ranks #961 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does QTRX compare to SEER and LAB in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), QTRX carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of 46.8%, and ROIC of -35.0%. By comparison, SEER (Seer Inc. (Class A)) holds a E grade (26/100 RQD, P/E N/A, ROIC -29.1%, cap $93.0M) and LAB (Standard BioTools Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -28.7%, cap $240.7M). Among the 5-stock peer group, QTRX leads on earnings multiple (N/A) while LAB leads on capital efficiency (-28.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for QTRX?
▼
Per QTRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001503274), Quanterix Corporation generated $138.9M in revenue (+1.1% YoY), -$107.2M in net income, and -$79.8M in free cash flow against $418.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.86 (-1.56%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (22/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-16.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QTRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (22/100 Composite)
🔍 WHY QTRX SCORES 22/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+5/20 pts (23% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (23% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$3.15-13.7% Next Q
30
Q2 (-2Q)Grade E$2.72+6.2% Next Q
27
Q3 (-1Q)Grade E$2.89+0.7% Next Q
25
CurrentGrade E$2.91-11.4% Hist 90D α
22
Trajectory: E (30) → E (22)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a QTRX Turnaround Squeeze
While QTRX currently carries a cautious 22/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.99) and Max Pain ($3.06) forces dealer call-delta covering toward $9.21.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $QTRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “QTRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why QTRX Stock dropped -7.63% Today — RQD Quant Desk Flash
Quanterix Corporation (QTRX) dropped -7.63% to $2.91, trading at 11% of its 52-week range ($2.15 – $8.77). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 11% of its 52-week range ($2.15 – $8.77) with RSI-14 at 46.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.91 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 46.8% gross margin and $0 annual free cash flow.
Live QTRX Headlines & Catalysts
MARKET WIREwww.marketscreener.com • 21h ago
Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026www.marketscreener.com report covering Quanterix Corporation (QTRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration ApprovalsYahoo Finance report covering Quanterix Corporation (QTRX) market action, institutional positioning, and fundamental catalysts.
CATALYSTInvesting.com UK • 1d ago
Quanterix partner receives China approval for neurology tests By Investing.comInvesting.com UK report covering Quanterix Corporation (QTRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
American Resources And 2 Other Promising Penny StocksSimply Wall St report covering Quanterix Corporation (QTRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
Quanterix stock: Q3 2026 results set for November 9ad-hoc-news.de report covering Quanterix Corporation (QTRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
SI-BONE, Inc. (SIBN) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Quanterix Corporation (QTRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Establishment Labs Holdings Inc. (ESTA) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Quanterix Corporation (QTRX) market action, institutional positioning, and fundamental catalysts.
CATALYSTBenzinga • 20d ago
TD Cowen Maintains Hold on Quanterix, Raises Price Target to $3.5TD Cowen analyst Dan Brennan maintains Quanterix (NASDAQ:QTRX) with a Hold and raises the price target from $3 to $3.5.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QTRX)
- ✓Walkthrough of QTRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
QTRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.65%🛡️ HOLDING TREND SUPPORT
2026-11-03O $3.15H $3.15L $2.91C $2.91VOL 361.3K
RES: $3.81SUP: $2.76SMA50: $2.99SMA200: $3.82
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
QTRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +1.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on QTRX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for QTRX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QTRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QTRX)
Health Care Rank #961 of 1016
⚔️ SEER vs QTRX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (QTRX vs. SEER, LAB, NAUT, HBIO)
Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Quanterix Corporation (QTRX) ranks #961 by composite RQD confidence (22/100, grade E) and #616 by equity capitalization ($137.4M). Within this direct 5-issuer industry benchmark cohort, QTRX leads on earnings valuation at N/A trailing P/E, while LAB leads on capital efficiency and profitability with -28.7% ROIC and 49.9% gross margin. HBIO currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with QTRX at 22/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| QTRX
ACTIVE
Quanterix Corporation | E | 22/100 | — | 46.8% | -35.0% | -7.63% | $137.4M | Benchmark Subject |
| SEER Seer Inc. (Class A) | E | 26/100 | — | 51.1% | -29.1% | -13.40% | $93.0M | /seer-vs-qtrx → |
| LAB Standard BioTools Inc. | E | 27/100 | — | 49.9% | -28.7% | -1.61% | $240.7M | /lab-vs-qtrx → |
| NAUT Nautilus Biotechnology Inc. | D- | 43/100 | — | — | -35.0% | -13.06% | $347.7M | /naut-vs-qtrx → |
| HBIO Harvard Bioscience Inc. | D | 47/100 | — | 57.7% | -35.0% | +1.14% | $40.5M | /hbio-vs-qtrx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001503274In its most recent audited fiscal period (FY2025, filed 2025-12-31), Quanterix Corporation (QTRX) reported GAAP revenue of $138.9M (+1.1% vs. FY2024 revenue of $137.4M , and +13.5% cumulative change since FY2023) , GAAP net income of -$107.2M, operating cash flow of -$77.2M, and free cash flow of -$79.8M (-107.2% YoY). On the balance sheet, QTRX closed FY2025 with $418.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $138.9M | -$107.2M | -$77.2M | -$79.8M | $418.8M | — |
| FY2024 (FY) | 2024-12-31 | $137.4M | -$38.5M | -$35.2M | -$38.5M | $406.5M | — |
| FY2023 (FY) | 2023-12-31 | $122.4M | -$28.4M | -$18.8M | -$18.8M | — | — |
3. QTRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs QTRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Quanterix Corporation (NASDAQ: QTRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $2.91 (-7.63% 1D, market cap $137.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, QTRX ranks #961 in composite RQD confidence.
How does QTRX compare to SEER and LAB in the Health Care sector?
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), QTRX carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of 46.8%, and ROIC of -35.0%. By comparison, SEER (Seer Inc. (Class A)) holds a E grade (26/100 RQD, P/E N/A, ROIC -29.1%, cap $93.0M) and LAB (Standard BioTools Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -28.7%, cap $240.7M). Among the 5-stock peer group, QTRX leads on earnings multiple (N/A) while LAB leads on capital efficiency (-28.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for QTRX?
Per QTRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001503274), Quanterix Corporation generated $138.9M in revenue (+1.1% YoY), -$107.2M in net income, and -$79.8M in free cash flow against $418.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is QTRX trading relative to its 50-day, 200-day, and 52-week technical levels?
QTRX last traded at $2.91 (-7.63% on volume of 361,309 shares), positioning the stock -2.68% below its 50-day simple moving average ($2.99) and -23.82% below its 200-day simple moving average ($3.82). Across its 52-week range of $2.15 to $8.77, QTRX sits at the 11.5% percentile with a 14-day RSI of 46.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.55 to $3.27).
QTRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is QTRX stock moving today?
Why QTRX Stock dropped -7.63% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 22/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
QTRX — Quanterix Corporation: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:42:40Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, QTRX scores 23 out of 100 with a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4/20 (ROIC of -35% and FCF yield of 0%); Whale 13F Flow at 6/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 5/20 (Beta 1.0 with sector sensitivity); and Forensic Balance Sheet at 5/20 (Altman Z 0.2, Piotroski F 3/9, Debt/Equity 0.5). Taken together, the weakest pillars are the cash engine and insider conviction, meaning the business is not currently generating returns on capital or cash, and insider activity provides little supportive signal. For a prospective investor, the upside case rests on a turnaround in operating economics that the source data does not show yet; the valuation tradeoff is that a market cap of $148.7M against operating margin of -60% and net margin of -60% leaves little margin for error. The Altman Z of 0.2 and Piotroski F of 3/9 point to elevated financial distress and weak fundamental quality, which are the forensic risks the verdict flags. This is an analytical reading of the scores, not a recommendation.
Business
Quanterix Corporation is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Laboratory Analytical Instruments industry. Per the profile, the company carries a market capitalization of $0.1B. The source data does not describe its product lines, customer base, or revenue model beyond the sector and industry classification. Reported revenue appears in the SEC financials, with FY 2025 revenue of $138.9M.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $138.9M | $-125.5M | $-107.2M | N/A | $-79.8M | $29.8M | N/A |
| FY 2024 | $137.4M | $-52.6M | $-38.5M | N/A | $-38.5M | $56.7M | N/A |
| FY 2023 | $122.4M | $-46.0M | $-28.4M | N/A | $-18.8M | N/A | N/A |
Per the SEC financials and market data, the company reported negative operating, net, and free cash flow across all three periods shown, with operating margin and net margin both at -60%. Gross margin is 46.8%, so the losses are driven by operating costs rather than gross profitability. ROIC is -35% and FCF yield is 0%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, with Debt/Equity of 0.5. Cash declined from $56.7M in FY 2024 to $29.8M in FY 2025.
Recent Catalysts & News Wire Analysis
- Earnings date: A headline reports that Quanterix will report third quarter 2026 financial results on November 9, 2026 (marked YELLOW, MARKET WIRE).
- China regulatory approvals: Headlines report that Quanterix and Innovita expanded IVD access in China with National Medical Products Administration approvals (YELLOW), and that a partner received China approval for neurology tests (GREEN, CATALYST).
- General coverage: Additional wire items are generic market-coverage pieces and a seasonal returns chart with no specific catalyst content in the summaries.
- Risk watch: The earnings release falls within the near-term window; the source summaries do not provide results or guidance.
- Proprietary signals: Per the Butterfly Supply-Chain Graph, none are present.
Open Questions
- What are the reported EPS, debt figures, and cash balances for FY 2023, since these are marked N/A or unavailable?
- What do the third quarter 2026 results (due November 9, 2026) show for revenue, margins, and cash burn?
- What drives the gap between the $0.1B market capitalization and the balance sheet indicators (Altman Z 0.2)?
- What is the commercial scale of the China approvals relative to total revenue?
- Which specific institutional holders and insider transactions underpin the whale-flow and insider-conviction pillar scores?
QTRX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Quanterix Corporation (QTRX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance UK • 18h ago
Quanterix Corporation (QTRX) Seasonal returns chart Yahoo Finance UK report covering Quanterix Corporation (QTRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.marketscreener.com • 21h ago
Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026 www.marketscreener.com report covering Quanterix Corporation (QTRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals Yahoo Finance report covering Quanterix Corporation (QTRX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Investing.com UK • 1d ago
Quanterix partner receives China approval for neurology tests By Investing.com Investing.com UK report covering Quanterix Corporation (QTRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
American Resources And 2 Other Promising Penny Stocks Simply Wall St report covering Quanterix Corporation (QTRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
Quanterix stock: Q3 2026 results set for November 9 ad-hoc-news.de report covering Quanterix Corporation (QTRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
SI-BONE, Inc. (SIBN) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Quanterix Corporation (QTRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Establishment Labs Holdings Inc. (ESTA) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Quanterix Corporation (QTRX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
QTRX Bull vs. Bear Conversation Board — What's Your Call at $2.91?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON QTRX 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $2.77 (-12.1%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is QTRX (E • RQD 23/100) a Buy at $3.15?
Welcome to the QTRX (Quanterix Corporation) Roar Pit. Current RQD Composite is 23/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Laboratory Analytical Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $2.61 (-17.1%)
Spot @ $3.15 Pump the brakes on QTRX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on QTRX, but look at what you are paying: current EV/EBITDA multiples with 46.8% gross margins. Unless Quanterix Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $3.94 (+25.1%)
Spot @ $3.15 QTRX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on QTRX, the market is fixating on short-term headline noise in Biotechnology: Laboratory Analytical Instruments and ignoring the balance sheet and cash flow trajectory. At $3.15 (52-wk range $2.15 - $8.77), any beat on forward guidance forces shorts and underweight funds to chase.